Scarica l'app Stockscreener
25.35
4.91%
-1.31
Dopo l'orario di chiusura:
25.43
0.08
+0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$26.66
Aprire:
$26.67
Volume 24 ore:
8.77M
Relative Volume:
0.87
Capitalizzazione di mercato:
$9.86B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-2.9038
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-7.78%
1M Prestazione:
+3.51%
6M Prestazione:
-7.68%
1 anno Prestazione:
-53.74%
Intervallo 1D:
$25.20
$26.90
Intervallo di 1 settimana:
$25.20
$27.37
Portata 52W:
$23.15
$57.69
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.35 | 10.41B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.39 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.48 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.91 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
836.39 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.29 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
US health agency fires official who opposed mRNA Covid shots - MarketScreener
New COVID vaccine says it’s for the ‘senior class’ — does it reduce side effects? - San Francisco Chronicle
AlphaQuest LLC Increases Position in Moderna, Inc. $MRNA - MarketBeat
Ethic Inc. Purchases 10,325 Shares of Moderna, Inc. $MRNA - MarketBeat
Why Moderna Inc. stock is a value investor pick2025 Retail Activity & Stock Portfolio Risk Management - Fundação Cultural do Pará
Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment - TipRanks
Will Moderna Inc. stock see insider buyingJuly 2025 Snapshot & Low Drawdown Trading Techniques - Fundação Cultural do Pará
Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud - Law360
What’s next for Moderna Inc. stock priceJuly 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Best data tools to analyze Moderna Inc. stockDollar Strength & Growth Oriented Trade Recommendations - newser.com
D.A. Davidson & CO. Purchases 62,778 Shares of Moderna, Inc. $MRNA - MarketBeat
Why Moderna Inc. stock is favored by top institutionsJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
Is Moderna Inc. meeting your algorithmic filter criteria2025 Institutional Moves & Accurate Trade Setup Notifications - newser.com
Is Moderna Inc. stock in correction or buying zonePortfolio Return Summary & Long-Term Capital Growth Ideas - newser.com
Analysts Set Expectations for Moderna FY2026 Earnings - MarketBeat
FY2026 EPS Estimates for Moderna Lowered by Analyst - MarketBeat
Equities Analysts Issue Forecasts for Moderna Q3 Earnings - MarketBeat
Moderna (NASDAQ:MRNA) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Is it too late to sell Moderna Inc.IPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Moderna scraps mRNA vaccine in congenital CMV on trial failure - Medical Dialogues
Using economic indicators to assess Moderna Inc. potentialPortfolio Update Report & Expert Approved Momentum Trade Ideas - newser.com
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Daily News Journal
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
How moving averages guide Moderna Inc. trading2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com
Moderna to Host Investor Event – Analyst Day - Shelby Star
Moderna Named a Top Employer by Science for Eleventh Consecutive Year - Bluffton Today
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Pueblo Chieftain
Moderna (MRNA) Outperforms Broader Market: What You Need to Know - Yahoo Finance
JPMorgan Chase & Co. Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00 - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap Down Following Analyst Downgrade - MarketBeat
UBS Maintains Moderna (MRNA) Buy Recommendation - Nasdaq
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - The Holland Sentinel
How Investors May Respond To Moderna (MRNA) Halting Development of mRNA-1647 CMV Vaccine - Yahoo Finance
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Asheville Citizen Times
Moderna, Inc. (MRNA) Stock Forecasts - Yahoo Finance
UBS Adjusts Moderna (MRNA) Price Target to $40, Maintains Buy Ra - GuruFocus
Moderna’s cytomegalovirus vaccine fails a phase III - BioWorld MedTech
Moderna Flunks Pivotal CMV Trial, But Read-Through Unlikely - Citeline News & Insights
Moderna (NASDAQ: MRNA) earns 11th straight Top Employer ranking in Science’s 2025 survey - Stock Titan
Healthcare Stocks Show Mixed Moves As Companies Shift Strategies - Finimize
COVID vaccines show an unexpected benefit: helping fight cancer - Fast Company
JP Morgan Lowers Price Target for MRNA to $25, Maintains Underwe - GuruFocus
Data supports usage of mRNA-1273.815 Covid-19 vaccine in young children - Clinical Trials Arena
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.28%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):